The start of a new wave: Developments in proteasome inhibition in multiple myeloma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901YVN" target="_blank" >RIV/61988987:17110/18:A1901YVN - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/18:E0107191
Result on the web
<a href="http://dx.doi.org/10.1111/ejh.13071" target="_blank" >http://dx.doi.org/10.1111/ejh.13071</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ejh.13071" target="_blank" >10.1111/ejh.13071</a>
Alternative languages
Result language
angličtina
Original language name
The start of a new wave: Developments in proteasome inhibition in multiple myeloma
Original language description
Multiple myeloma (MM) accounts for 10% of hematological cancers. Stem cell transplantation remains the cornerstone of first-line treatment for eligible patients, but historically, pharmaceutical treatment options for MM have been limited. The proteasome was identified as a target for MM therapy in the early 2000s and, in 2004, the boronic acid proteasome inhibitor bortezomib gained European approval. Bortezomib now plays a major role in MM treatment, but the duration of its use can be limited by toxicities such as peripheral neuropathy and the development of resistance. A new generation of proteasome inhibitors has since entered the treatment landscape: carfilzomib, an epoxyketone-based agent with a distinct mode of action, high clinical efficacy, and lower levels of peripheral neuropathy compared with bortezomib, received approval in 2015 for use in patients with relapsed and/or refractory MM (RRMM). Ixazomib, a second-generation, orally administered, boronic acid proteasome inhibitor, has also been approved for use in patients with RRMM. In just over a decade, proteasome inhibitor-based regimens have become an integral component of MM treatment; with more proteasome inhibitors in development, this remains a vibrant research area with potential to improve the lives of patients with MM in the years to come.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
EUROPEAN JOURNAL OF HAEMATOLOGY
ISSN
0902-4441
e-ISSN
1600-0609
Volume of the periodical
2
Issue of the periodical within the volume
101
Country of publishing house
US - UNITED STATES
Number of pages
17
Pages from-to
220-236
UT code for WoS article
000439773500013
EID of the result in the Scopus database
2-s2.0-85046335606